Delivery Order SPE2DB20D3101-SPE2DB21FK3S2
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,984.20 firm fixed-price delivery order is for the supply of Omnipaque 350 mg/ml infusion bottles, a radiopaque contrast agent used in medical imaging procedures. The contract has a completion date of July 31, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award, valued at $1,365.73, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of OMNIPAQUE 350 MG/ML INFU BTL 100ML, a pharmaceutical product, with a completion date of July 24, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
- This federal contract award, valued at $1,690.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a medical product, with a period of performance through January 7, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- This federal contract award, valued at $15,004.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OMNIPAQUE 240 MG/ML, a medical product, with an ultimate completion date of April 21, 2023. This award does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $1,173.23 firm fixed-price delivery order is for the supply of OMNIPAQUE 350 MG/ML INFU BTL 100ML, a pharmaceutical product, with a completion date of June 18, 2024. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,050.18, is for the delivery of OMNIPAQUE 350 MG/ML INFU BTL 100ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of October 26, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,197.84 firm fixed-price delivery order is for the supply of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a pharmaceutical product, with a period of performance through October 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,464.91 firm fixed-price delivery order is for the supply of OMNIPAQUE 350 MG/ML INFU BTL 100ML, a medical product used in healthcare. The award does not have a set-aside designation, indicating it was open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the U.S. Department of Defense (DoD) Medical Supply Chain for the supply of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a pharmaceutical product. The $6,867.92 delivery order contract is a firm fixed-price arrangement without any set-aside designation. Amerisourcebergen also holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,769.38 firm fixed-price delivery order is for the supply of OMNIPAQUE 300 MG/ML PLUSPAK 500ML, a pharmaceutical product, with a period of performance through October 2024. This contract is not designated as a set-aside and represents an open competition award. Amerisourcebergen holds a significant $999,999,999...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB21FK3S2Delivery Order
This federal contract award, valued at $1,218.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Omnipaque 350 mg/ml infusion bottles, a critical pharmaceutical product. The award is a delivery order placed under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. No set-aside designation was used for this specific award. In addition to the DLA contract, Amerisourcebergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/27/21 |